Biogen’s Tecfidera Resilience Reflects ‘Inefficiencies In US System’
Payment Quirk Also Means Doctors Currently ‘May Prefer Vumerity’
Analysts in Q3 pounced on a quirk in the complex US healthcare system that has provided small relief to Biogen’s much-depleted Tecfidera franchise in the US in the face of many generic rivals.
You may also be interested in...
As anticipated by the street, Viatris has prevailed over Biogen on the originator’s appeal of a district court ruling that invalidated a key US patent shielding its Tecfidera treatment for multiple sclerosis. However, the Federal Circuit was not aligned on its decision.
Viatris will host another investor day, to take place early in the new year, to discuss its 2022-23 and 2024+ plans. Management provided details during the company’s Q3 earnings call, as Viatris announced it was once again raising full-year financial targets.
In November, ANI Pharmaceuticals is hoping to complete a major acquisition, Viatris may shed further light on the state of the US generics industry and Generics Bulletin will host its eighth annual Global Generics & Biosimilars Awards, this year once again in person.